Stilla Technologies adds 20 new oncology liquid biopsies kits to its reagents portfolio from partner ApexBio
18.4.2023 16:07:00 EEST | Business Wire | Press release
Stilla Technologies today announced the availability of 20 new digital PCR assays, optimized for its Crystal Digital PCR™ platform, the naica® system, to be utilized for the detection of circulating tumor DNA (ctDNA) from liquid biopsy samples. Produced by distributor and technology partner ApexBio, these digital PCR kits are designed for the absolute quantitation of nucleic acids from genetic mutations found across a widespread range of oncological indications.
“The release of these assays, in addition to our other available ready-to-use kits, is a continuation of Stilla’s strategy to offer an ever-growing menu of content covering an increasing number of clinically-relevant biomarkers,” says Remi Dangla, Founder and Chief Technology Officer at Stilla Technologies. “By expanding the volume of gene targets available for interrogation in patient samples using an easy-to-perform digital PCR test, we’re empowering research and clinical scientists to leverage their own labs in order to get answers to their biological questions, in a matter of just a couple of hours.”
The naica® system, the flagship digital PCR platform from Stilla Technologies, is used across a broad spectrum of applications, including oncology, cell and gene therapy, and environmental testing. The company offers off-the-shelf digital PCR kits for use on the naica® system, as well as assay development services for custom assay design.
Stilla Technologies is currently exhibiting at the Annual Meeting meeting of the American Association of Cancer Research (AACR) where the naica® system will be featured in several scientific posters, including research in collaboration with Promega Corporation, Atila Biosystems, and University of Athens. More information on Stilla product offerings and scientific posters can be obtained at Stilla’s exhibition booth #3172 from our scientific specialists.
About Stilla Technologies
Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla’s groundbreaking Crystal Digital PCR™ solution, the naica® system, is the industry’s first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market. Stilla has U.S. headquarters in Boston, MA, European headquarters in Paris, France, and strategic distribution and business partnerships in China and throughout EMEA. To learn more, visit www.stillatechnologies.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005848/en/
Contact information
Media contact - Christopher Hynes
christopher.hynes@stillatechnologies.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vultr, SUSE & Supermicro Debut Unified Cloud-to-Edge Architecture for Global AI Scaling6.5.2026 15:00:00 EEST | Press release
Vultr, the world's largest privately-held cloud infrastructure company, in collaboration with SUSE and Supermicro, today announces a strategic architectural framework designed to solve the complexities of deploying and operating AI workloads across distributed environments. As AI moves closer to the point of data creation - from manufacturing floors to retail storefronts - organizations face significant challenges in latency, cost and operational consistency. This joint initiative provides a seamless, Cloud-to-Edge pipeline that integrates high-performance hardware, localized cloud infrastructure, and unified Kubernetes management. The partnership addresses the reality that sending all data back to a central cloud is no longer viable for real-time AI. The solution breaks down the infrastructure into three critical layers: The Cloud and Near-Edge - Enterprises can deploy regional Kubernetes-based AI clusters closer to their users by leveraging Vultr’s 33 global cloud data center regions
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program6.5.2026 15:00:00 EEST | Press release
Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program. With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solutions across the full drug development lifecycle. Under the collaboration, Waiv will apply its end-to-end computational pathology platform to early phase data. This includes tumor microenvironment (TME) analysis across both hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stained samples, as well as biomarker discovery and outcome prediction capabilities aimed at identifying biomarkers of treatment response ahead of next clinical trial phases. Purpose-built AI approach tackles one of pharma's hardest challenges: b
Elisa Expands PON Deployment with Vecima’s All-PON™ Shelf, Delivering 10G Fiber Services in Estonia6.5.2026 14:30:00 EEST | Press release
Vecima Networks Inc. (TSX: VCM) announced today that leading telecommunications operator Elisa has deployed Vecima’s Entra EXS1610 All-PON™ Shelf for 10G Fiber-to-the-Home (FTTH) services for its subscribers in Estonia. In Estonia’s competitive broadband market, Elisa brings highly innovative solutions to its subscribers. Vecima’s EXS1610 supports multiple deployment use cases, including greenfield, targeted brownfields, rural edge-outs, hybrid fiber-coax (HFC) overbuilds, footprint extensions, and hub collapses. Its compact shelf footprint can help reduce operating costs and allow operators to deploy anywhere – for maximum flexibility, including data centers, remote cabinets, the headend, and multi-dwelling units. The Entra EXS1610 All-PON Shelf features: 16 x PON ports: 10G-EPON, XGS-PON, and Combo XGS-PON & GPON Temperature-hardened for outside plant deployments Multi-vendor optical network terminal (ONT) interoperability Uplink optics: 2 x 100/40G & 2 x 25/10G with broad third-part
Vertex Announces CASGEVY ® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany6.5.2026 14:01:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia. “For the first time in Germany, a long-term, sustainable access agreement to a gene therapy has been established for people living with sickle cell disease and transfusion-dependent beta thalassemia,” said Ludovic Fenaux, Senior Vice President, Vertex International. “This agreement represents significant progress for people living with these two devastating and life-shortening diseases. We are pleased to collaborate across the health care system to ensure the value of CASGEVY is recognized and sustainable patient access is secured.” With this agreement, German
NIQ Launches AI-Powered Platform to Help Brands Test Pricing Decisions Before They Go to Market6.5.2026 14:00:00 EEST | Press release
As manufacturers face mounting pressure to protect margins, justify trade spend, and respond faster to shifting consumer demand, NIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the commercial launch of Price & Promo Optimizer, a next‑generation, AI‑enabled Revenue Growth Management (RGM) platform built to fundamentally change how pricing and promotion decisions are made. Today, many pricing and promotion decisions are still made across disconnected tools, manual workflows, and siloed teams—slowing execution, increasing risk, and limiting the ability to validate strategies before they reach the market. Price & Promo Optimizer replaces this fragmented approach with a united platform that brings pricing, promotion, and trade strategy into a single workflow. Powered by NIQ’s trusted store‑level measurement data and advanced analytical models, Price & Promo Optimizer enables category managers, RGM leaders, marketing, and commercial teams to simulate scenarios, qua
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom